Any current/future new fundraising through debt or equity?

As of the November 20, 2023 earnings call, NGL Fine-Chem Limited stated they are funding capital expenditures (capex) from internal accruals generated from business operations. They have not leveraged their balance sheet yet and are maintaining a measured execution pace on capex. The company is cautious and plans to decide on accelerating the capex and related investments early next calendar year. There was no mention of any current or planned fundraising through equity or external debt during the call or in the transcript. The company aims to avoid borrowing funds until there are more definit

Any current/future capex/capital investment/strategic investment?

NGL Fine-Chem is cautiously progressing with its Greenfield capex primarily aimed at regulated markets. Approximately 90% of RCC civil work for the Greenfield facility is completed. Some long lead-time equipment has been ordered, but full commitment to machinery installation awaits confirmation of demand recovery. The pilot plant for the Greenfield facility is scheduled to start by Q1 FY25, ahead of the full plant completion, to speed up product validation. Full Greenfield project completion is expected within 12-15 months once machinery installation begins. The company plans to take a final d

Future growth expectations in sales/revenue/volumes?

The company is cautiously optimistic about demand recovery, currently at the bottom of the price realization bell curve, expecting improvements going forward. Targeting revenue growth to INR350-400 crores with existing capacity plus some outsourcing; reaching INR450 crores seen as ambitious. Product development is strong, aiming to expand product basket to 35 APIs by FY2025. Focus on adding 2-3 new products annually, including higher volume products that offer China Plus One sourcing alternatives. Greenfield capex is progressing; pilot plant expected operational by Q1 FY2024; full plant comple

Future growth expectations in earnings/operating earnings/profits/EPS?

The company is cautiously optimistic about a demand recovery but remains watchful due to geopolitical uncertainties and currency issues in some markets. Long-term EBITDA margin guidance remains in the 17%-22% range; current margins are at the lower end and expected to improve to a median level over time. Revenue growth is primarily driven by volumetric growth and a broader, diversified product basket, with product concentration reducing. The company does not provide specific forward guidance on turnover, profits, or EPS. Greenfield capex and new product introductions (targeting 35 APIs by 2025

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders by NGL Fine-Chem Limited. However, there is mention of ongoing product registrations and approvals: - Filed for CEP (Certificate of Suitability to the European Pharmacopoeia) for 3 products; approvals delayed due to slower regulatory processing post-COVID, expected in about six more months. - Filed 5 Drug Master Files (DMF) in various European countries, currently under registration. Commercial production is ongoing for 28 products. The company is cautiously optimistic about demand recovery and

NGL Fine Chem LtdQ2 FY24Pharmaceuticals & Biotechnology

NGL Fine Chem Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,612.8P/E: 32.0Market Cap: ₹1.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

The company is cautiously optimistic about demand recovery, currently at the bottom of the price realization bell curve, expecting improvements going forward.
Targeting revenue growth to INR350-400 crores with existing capacity plus some outsourcing; reaching INR450 crores seen as ambitious.
Product development is strong, aiming to expand product basket to 35 APIs by FY2025.
Focus on adding 2-3 new products annually, including higher volume products that offer China Plus One sourcing alternatives.
Greenfield capex is progressing; pilot plant expected operational by Q1 FY2024; full plant completion targeted within 12-15 months after final investment decision anticipated early next year.
The company intends to maintain EBITDA margins in the 17%-22% range during growth.
Geographic expansion continues with gains in East Asia, Europe, and Latin America, while West Asia and Africa face currency challenges.
Overall, growth depends on market recovery and geopolitical stability.

Margin guidance

Category 3

The company is cautiously optimistic about a demand recovery but remains watchful due to geopolitical uncertainties and currency issues in some markets.
Long-term EBITDA margin guidance remains in the 17%-22% range; current margins are at the lower end and expected to improve to a median level over time.
Revenue growth is primarily driven by volumetric growth and a broader, diversified product basket, with product concentration reducing.
The company does not provide specific forward guidance on turnover, profits, or EPS.
Greenfield capex and new product introductions (targeting 35 APIs by 2025) aim to drive future growth, but significant expansion decisions will be taken cautiously by early next year.
Operating leverage and capacity utilization improvements (including pilot plant commissioning in Q1 FY25) are expected to aid revenue and margin growth.
No major pricing power is expected due to the B2B generic nature of the business amidst competition.

See what NGL Fine Chem Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

As of the November 20, 2023 earnings call, NGL Fine-Chem Limited stated they are funding capital expenditures (capex) from internal accruals generated from business operations.
They have not leveraged their balance sheet yet and are maintaining a measured execution pace on capex.
The company is cautious and plans to decide on accelerating the capex and related investments early next calendar year.
There was no mention of any current or planned fundraising through equity or external debt during the call or in the transcript.
The company aims to avoid borrowing funds until there are more definitive signs of demand recovery before expediting capex spend.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders by NGL Fine-Chem Limited.
However, there is mention of ongoing product registrations and approvals:
- Filed for CEP (Certificate of Suitability to the European Pharmacopoeia) for 3 products; approvals delayed due to slower regulatory processing post-COVID, expected in about six more months.
- Filed 5 Drug Master Files (DMF) in various European countries, currently under registration.
Commercial production is ongoing for 28 products.
The company is cautiously optimistic about demand recovery and is monitoring market conditions before accelerating capex or expansion.
There is a strategic focus on expanding the product basket, targeting 35 APIs by 2025.
No specific figures on order book or pending orders were disclosed in this call.

See what NGL Fine Chem Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

NGL Fine-Chem is cautiously progressing with its Greenfield capex primarily aimed at regulated markets.
Approximately 90% of RCC civil work for the Greenfield facility is completed.
Some long lead-time equipment has been ordered, but full commitment to machinery installation awaits confirmation of demand recovery.
The pilot plant for the Greenfield facility is scheduled to start by Q1 FY25, ahead of the full plant completion, to speed up product validation.
Full Greenfield project completion is expected within 12-15 months once machinery installation begins.
The company plans to take a final decision on accelerating capex early next calendar year based on market conditions.
Current capital expenditures are being funded internally, avoiding increased leverage on the balance sheet.
There is also a plan to increase outsourcing capacity modestly within the next 2-3 quarters.

Track NGL Fine Chem Ltd — get its next earnings analysis in your feed

How does NGL Fine Chem Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisNGL Fine Chem Ltd

Rev 3Mar 3

See where NGL Fine Chem Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does NGL Fine Chem Ltd rank in Pharmaceuticals & Biotechnology?

Compare NGL Fine Chem Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What NGL Fine Chem Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

NGL Fine Chem Ltd Q2 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does NGL Fine Chem Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What NGL Fine Chem Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season